CardioSystemPharma

CardioSystemPharma is a clinical-stage biotechnology company focused on developing innovative solutions for cardiac protection during surgical procedures and emergency medical events. The company's lead candidate, CSP-001, is a novel cardioplegic solution designed to improve myocardial preservation and patient outcomes during open-heart surgery. By optimizing the metabolic environment of the heart during induced arrest, CardioSystemPharma aims to reduce post-operative complications and accelerate recovery. The company is primarily active in the Russian pharmaceutical market and has conducted significant clinical trials within that region.